A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease

StatusUnknown
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
  2. Primary completion date changed from estimate of Nov 2024 to Nov 30, 2024v4
  3. Primary endpoints revised (2)v3 Show 5 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 240 to confirmed 255
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: 6 to 7
    • Site details revised
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2023 to May 23, 2023
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of SC0062 capsule in patients with chronic kidney disease (diabetic kidney disease and IgA nephropathy)with albuminuria compared to matching placebo.
Trial Details
NCT Number NCT05687890
Lead Sponsor Biocity Biopharmaceutics Co., Ltd.
Conditions
(from sponsor)		 Diabetic Kidney Disease, IgA Nephropathy
Related terms Diabetic Nephropathies, Glomerulonephritis, IGA
Enrollment 255 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov